Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ASI Non-Invasive Arterial Stiffness Screening Device (ASI Device) is an investigational device under development for the non-invasive assessment of arterial stiffness. The ASI Device is considerably smaller and more cost effective than its commercially available counterparts. As the device is readily portable, it is intended to be targeted for use in the community (or at home), as opposed to within the hospital or clinic setting only. However, as the device is still under development, it is not known whether it is capable of determining arterial stiffness with the same sensitivity and consistency as those already in commercial use. An added variable is the fact the sensor for the ASI Device is located on the fingertip.

Validation is a prerequisite for obtaining Health Canada approval of devices for diagnostic purposes. The ASI Device has not been tested against other instruments capable of providing similar measurements. Therefore, a clinical trial to compare the ASI Device against similar devices is necessary. The study will compare measurements of arterial stiffness and other central haemodynamic parameters obtained with the ASI Device against similar measurements from devices that have already been approved for this purpose by Health Canada/United States Food and Drug Administration (FDA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing the Safety and Efficacy of a Novel Subcutaneous Implant Insertion Device on Healthy Adults

NCT03621787

Healthy

TERMINATED NA

Evaluation of the Pantheris Atherectomy System

NCT01937351

Peripheral Arterial Disease

COMPLETED NA

Blood Collection for Development and Validation of Point-of-Care Diagnostic Liver Function Tests

NCT05457543

Liver Diseases Healthy Liver Cirrhosis +1 more

UNKNOWN

Evaluation of the A1CNow+ Test Kit

NCT00798486

Diabetes

COMPLETED NA

A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease

NCT00516308

Peripheral Vascular Diseases

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an exploratory, proof of concept, open sequential registration comparative study designed to establish the utility and accuracy of the ASI Non-Invasive Arterial Stiffness Screening Device (ASI-Device) for the non-invasive vascular assessment of arterial stiffness relative to other such devices already approved and commercially available in Canada and the United States.

The pressure exerted from the contraction of the heart creates a wave form, which travels down the individual's arterial trunk to all parts of the body. The velocity (speed) at which this wave form travels can serve as an indicator of the degree of arterial stiffness. The faster the speed of travel of the pulse wave the stiffer the arteries. It has been demonstrated in other studies that the contour (shape) of the waveform can be affected by the pulse wave velocity and that analysis of this shape is an acceptable surrogate for determining the pulse wave velocity and ultimately determining the severity of arterial stiffness. This method of analysing the contour of the pulse wave to determine the severity of arterial stiffness is called pulse wave analysis (PWA).

The ASI Device non-invasively measures the severity of arterial stiffness derived through pulse wave analysis. The study will compare measurements of arterial stiffness and other central haemodynamic parameters, as derived through pulse wave analysis obtained with the ASI Device, against similar measurements from the SphygmoCor Px System from AtCor and the CR-2000 CV Profiler from Hypertension Inc, devices that already have approval for this purpose by Health Canada and/or the United States Food and Drug Administration.

Three groups of individuals will be sought;

1. Healthy participants (n=25)
2. Persons with Type 2 Diabetes and/or Obesity (n=15)
3. Persons with a diagnosed Cardiovascular/Vascular disease (such as CAD or PAD) (n=15)

Participants will be asked to provide written informed consent prior to participation in the study. Eligible participants will be asked to attend an in-person visit where they will undergo the non-invasive vascular testing. Testing will be comprised of:

1. Pulse Wave Analysis using the ASI Device
2. Pulse Wave Analysis using the SphygmoCor Device
3. Pulse Wave Analysis using the CR-2000 CV Profiler

Although pulse wave contour analysis (PWA) has been demonstrated to be an acceptable surrogate for the assessment of arterial stiffness, Pulse Wave Velocity has been the gold standard for the assessment of arterial stiffness. As such, the VP-1000, a non-invasive vascular screening device, will also be used to measure pulse wave velocity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Diabetes Type 2 Obesity Coronary Artery Disease Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ASI Device

Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.

Group Type EXPERIMENTAL

ASI Device

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ASI Device

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ASI Non-Invasive Arterial Stiffness Screening Device

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants of the Healthy Group must meet the following criteria to be eligible for participation in the study:

1. Healthy male or female, greater or equal to 20 and less than or equal to 70 years of age;
2. Willing to comply with the protocol requirements;
3. Willing to provide informed consent.

Participants of the Obese/Type 2 Diabetes Group must meet the following criteria to be eligible for participation in the study:

1. Male or female, greater or equal to 20 and less than or equal to 70 years of age;
2. Presence of clinically diagnosed Type 2 Diabetes, and/or a body mass index (BMI) \> 30;
3. Willing to comply with the protocol requirements;
4. Willing to provide informed consent.

Participants of the Vascular Disease Group must meet the following criteria to be eligible for participation in the study:

1. Male or female, greater or equal to 20 and less than or equal to 70 years of age;
2. Documented evidence of atherosclerosis as manifested by one of the following:

1. documented myocardial infarction;
2. documented CAD as defined as \>70% stenosis of an epicardial coronary artery;
3. documented PAD including those with claudication as defined by an ankle brachial index of \<0.9;
4. angiographically documented carotid or lower limb stenosis of \>50%
3. Willing to comply with the protocol requirements;
4. Willing to provide informed consent -

Exclusion Criteria

Participants of the Healthy Group will be excluded if they have any of the following:

1. Presence of a clinically diagnosed disease affecting the circulatory, respiratory, immune, skeletal, urinary, muscular, endocrine, digestive, nervous or reproductive system that requires medical treatment;
2. Cigarette/cigar smoking, current or within the last 6 months;
3. Current (within the last 30 days) bacterial, viral or fungal infection;
4. Taking any prescribed medication (with the exception of birth control or HRT) within the last 3 months or over-the-counter medication within the past 72 h;
5. Pregnancy;
6. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.

Participants of the Obese/Type 2 Diabetes Group will be excluded if they have any of the following:

1. Documented evidence of atherosclerosis as manifested by one of the following:

1. documented myocardial infarction;
2. documented CAD as defined as \>70% stenosis of an epicardial coronary artery;
3. documented PAD including those with claudication as defined by an ankle brachial index of \<0.9;
4. angiographically documented carotid or lower limb stenosis of \>50%
5. having had a documented previous intervention for CAD or PAD.
2. Cigarette/cigar smoking, current or within the last 6 months;
3. Current (within the last 30 days) bacterial, viral or fungal infection;
4. Taking over-the-counter medication within the past 72 h;
5. Pregnancy;
6. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.

Participants of the Vascular Disease Group will be excluded if they have any of the following:

1. Cigarette/cigar smoking, current or within the last 6 months;
2. Current (within the last 30 days) bacterial, viral or fungal infection;
3. Taking over-the-counter medication within the past 72 h;
4. Pregnancy;
5. Amputation or malformation of any limb or extremity (fingers, leg, or arm) which would impede the placement of sensors, probes, or blood pressure cuffs.
6. Having had a documented previous intervention for CAD or PAD

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes